BioSpace1h
GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...
GSK sees FY25 core EPS growth 6%-8%
GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...
GSK lifts long-term sales targets on new drug pipeline
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It ...
FierceBiotech4h
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...
GSK boosts 2031 revenue target to over £40bn following robust Q4 results
The pharma giant hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth ...
Macau Business1h
GSK sees annual profit slide on Zantac drug fallout
British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.